Inovio Pharmaceuticals, Inc.
INO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $13 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $13 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -73.8% | -91.9% | 478.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -47,735.2% | -15,671.8% | -2,639.8% | -16,709.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -49,254.3% | -16,239.9% | -2,726.7% | -17,109.9% |
| EPS Diluted | -3.95 | -6.09 | -14.07 | -1.42 |
| % Growth | 35.1% | 56.7% | -890.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |